药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
6期
524-526
,共3页
口服降糖药%二肽基肽酶Ⅳ(DPP-4)抑制剂%多器官保护作用
口服降糖藥%二肽基肽酶Ⅳ(DPP-4)抑製劑%多器官保護作用
구복강당약%이태기태매Ⅳ(DPP-4)억제제%다기관보호작용
Oral antidiabetic drug%Dipeptidyl peptidase inhibitors Ⅳ(DPP-4)%Multiple organ protection
二肽基肽酶Ⅳ（DPP-4）抑制剂是近年来新上市的一种新型口服降糖药物。 DPP-4抑制剂通过抑制DPP-4来抑制胰岛素多肽（GIP）和胰高血糖素样肽1（GLP-1）降解，发挥降低血糖的作用。 DPP-4抑制剂不仅能双向控制血糖，且具有降糖外的胰腺、心血管、肾脏、肝脏等多器官保护作用和抗炎作用。本文对已有的DPP-4抑制剂及其多器官保护作用进行综述，总结其优势及进一步发展的趋势，为临床用药提供参考。
二肽基肽酶Ⅳ（DPP-4）抑製劑是近年來新上市的一種新型口服降糖藥物。 DPP-4抑製劑通過抑製DPP-4來抑製胰島素多肽（GIP）和胰高血糖素樣肽1（GLP-1）降解，髮揮降低血糖的作用。 DPP-4抑製劑不僅能雙嚮控製血糖，且具有降糖外的胰腺、心血管、腎髒、肝髒等多器官保護作用和抗炎作用。本文對已有的DPP-4抑製劑及其多器官保護作用進行綜述，總結其優勢及進一步髮展的趨勢，為臨床用藥提供參攷。
이태기태매Ⅳ（DPP-4）억제제시근년래신상시적일충신형구복강당약물。 DPP-4억제제통과억제DPP-4래억제이도소다태（GIP）화이고혈당소양태1（GLP-1）강해，발휘강저혈당적작용。 DPP-4억제제불부능쌍향공제혈당，차구유강당외적이선、심혈관、신장、간장등다기관보호작용화항염작용。본문대이유적DPP-4억제제급기다기관보호작용진행종술，총결기우세급진일보발전적추세，위림상용약제공삼고。
Dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a new type of oral antidiabetic drugs appeared in recent years, which provides new approaches for the treatment of type 2 diabetes. DPP-4 inhibitors currently include five drugs as sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin. Most animal experiments and clinical trials proved that DPP-4 inhibitors could not only control blood sugar bidirectionally, but also show positive effects on organs like pancreas, cardiovas_cular, kidney and liver. This article summarizes the knowledge of DPP-4 inhibitor and their multi-organ protective effects, to show the advantages and further development trends, and to provide reference for clinical use.
